Conference on pharmaceutical quality assurance through good manufacturing practices held in Mysuru
It was held in association with the Indian Pharmaceutical Association, Mysuru branch, along with other organisations, and included a session on Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS).
A release said that the initiative aimed to ensure consistent production and control of medicinal products to meet the highest quality standards.
The primary objective of the conference was to promote the understanding and implementation of Good Manufacturing Practice (GMP) principles among pharmaceutical manufacturers, emphasising the importance of adherence to GMP standards for ensuring the safety, efficacy, and quality of medicinal products, the release added.
The conference also aimed to provide guidance on incorporating GMP requirements into national medicine laws and regulations, while facilitating the exchange of best practices in GMP implementation. The conference was inaugurated by Dr. Khalid Ahmed Khan, Deputy Drug Controller and president of the Indian Pharmaceutical Association (IPA), Karnataka State branch.
Dr. H. Basavana Gowdappa, the vice chancellor of JSS Academy of Higher Education & Research, Mysuru, urged the industry to view GMP not merely as a regulatory requirement, but as a core responsibility.
Dr. Amaresh Tumbagi, former Drug Controller of the Karnataka government, highlighted various inspections conducted under Schedule M and discussed how regulatory bodies have evolved with the revised version.
Dr. Pramod Kumar T.M., Principal, JSS College of Pharmacy, Mysuru, provided insights into industry and government regulations related to GMP. Around 100 delegates from different industries and academics were present apart from the members of IPA Mysuru branch.
Dharmendra Kumar Yadav, Under Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, Yashwant Shinde, Manager, Small Industries Development Bank of India (SIDBI), and Dr. R.S. Savitha, Secretary, IPA Mysuru, were among those present.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
6 days ago
- Hans India
Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India
Cohance Lifesciences Limited ('Cohance' or 'the Company'), a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities. Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the Company to take these high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production. Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26. Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: 'Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.' This investment follows the Company's recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.
The Hindu
6 days ago
- The Hindu
Cohance to invest $10 million to expand capabilities of U.S. arm, ₹23 cr. in new facility at Hyderabad
Global contract research, development and manufacturing organisation Cohance Lifesciences on Tuesday said it will invest $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary NJ Bio. In another announcement, Cohance said it will be investing ₹23 crore on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The investment in the U.S. will advance its global expansion in niche technology-led modalities, enhancing ability to support innovators from early development through late-phase clinical supply. The build-out of a cGMP compliant bioconjugation suite at NJ Bio's Princeton, New Jersey facility strengthens the company's capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions, Cohance said. The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter. On the investment on the cGMP Oligonucleotide facility in Hyderabad, Cohance (formerly known as Suven Pharma) said the facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. It will enable the company to take high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Customer engagements are underway, with audits planned in coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence by December. Cohance said the two investments are part of planned capacity expansion programme across high-growth modalities enhancing its ability to serve global innovators from early development to commercial supply.
Business Standard
6 days ago
- Business Standard
The Indian Wellness Revolution: How Ancient Wisdom is Powering the Future of Health
The world is finally turning its attention to what India has known for centuries. From turmeric lattes to yoga studios on every corner, ancient Indian traditions are no longer just a part of our heritage—they are a global wellness phenomenon. Consumers everywhere are moving away from synthetic, one-size-fits-all solutions, seeking natural, holistic remedies that address the root cause of health concerns. At the heart of this global shift are Ayurveda and Unani, two powerful systems of medicine now taking the global stage. From Tradition to Trust: The Power of Ayurveda and Unani Ayurveda, the "science of life," and Unani, the "science of healing," are more than just herbal remedies; they are comprehensive systems of living that focus on balance and harmony within the body. These traditions teach us that true health is about prevention and addressing imbalances before they become diseases. Auffüllen proudly carries this torch, integrating the potent wisdom of these ancient systems into its formulations. Our products feature powerful Ayurvedic herbs like Guduchi (Tinospora cordifolia) and Unani herbs such as Habb al Sawda (Nigella sativa), renowned for their comprehensive health benefits. This is where the old meets the new—where time-tested ingredients are recognized for their profound impact on modern health challenges. Auffüllen: Where Ancient Wisdom Meets Modern Science While our cultural heritage provides the foundation, Auffüllen's true innovation lies in its ability to fuse this ancient wisdom with cutting-edge modern science. We are not just a traditional remedy brand; we are a scientifically-backed nutraceutical solution for today's world. Auffüllen's patent-pending formulation represents a new frontier in holistic nutrition. With over 66 clinically studied ingredients, it blends the traditional wisdom of Ayurvedic and Unani herbs with the scientifically validated Botanical full spectrum of essential vitamins, minerals, and amino acids. This all-in-one supplement is designed to simplify modern nutrition, eliminating the need for multiple products and offering a complete, convenient solution for daily wellness. Every Auffüllen product is meticulously formulated to be your proactive partner in wellness, offering "insurance against disease." This is not about a quick fix; it's about replenishing your health for generations by improving it today. Scientific Validation: Building Authority and Trust We understand that modern, health-conscious consumers demand more than just promises. They require proof. That's why Auffüllen is committed to the highest standards of quality and transparency. Our products are backed by: Clinical Research: Over 30 years of research and global collaboration have gone into our formulations. Rigorous Certifications: We are certified by globally recognized bodies such as UKAS, HACCP, GMP, UAF, and IAF, ensuring the highest standards in manufacturing practices and product quality Dietary Compliance: We are proud to be FSSAI, Halal, and Kosher certified, making our products accessible to a wider audience with varying dietary needs and beliefs. Join the Wellness Revolution With Auffüllen Auffüllen is more than a supplement; it's a celebration of our culturally rich heritage, meticulously engineered for a globally relevant, modern audience. It's a proactive step towards a healthier, more vibrant life, grounded in ancient wisdom and validated by modern science.
